Apoglyx is a pre-clinical stage virtual biotech company with the aim to develop an oral therapy for type 2 diabetes patients, which are not adequately addressed by standard therapy. The treatment concept is based on the studies of Swedish and Danish researchers, which have discovered a novel mechanism for inhibiting hepatic glucose production.
Preben Bruun-Nyzell is an executive with more than 20 years international experience. He is co-founder of 2A Pharma and served as CFO from 2016-2019. He was previously Chief Financial Officer of Qatalum in Qatar, an aluminum producer with annual sales of USD 1.5 billion, and has held senior positions with EMAL in Abu Dhabi, Arqaam Capital in Dubai, Accenture and PwC in London and Hoffmann-La Roche AG in Basel, Switzerland. Preben holds a degree in Business Administration from Lancaster University in the UK and Università Bocconi, Milan, Italy.